Ipamorelin Dosage: What the Research Reports

What does the research report about ipamorelin dosage?

The clearest peer-reviewed data comes from Raun et al. (1998), an animal study, so published ipamorelin dosing is preclinical rather than a settled human protocol.

In that paper, ipamorelin released GH in a dose-dependent way in anaesthetized rats and conscious swine, with potency and efficacy the authors described as comparable to GHRP-6 (Raun et al., 1998). The study's aim was to characterize a new secretagogue, not to define a human treatment dose. That distinction matters: much of what people find when they search "ipamorelin dosage" is a set of microgram figures repeated across forums and clinics, and those numbers are not drawn from a completed human dose-ranging trial.

Because of that gap, the responsible summary is simple. Research describes how ipamorelin acts and at what relative potency in animals. It does not hand the public a validated human dose.

What is ipamorelin and how does it work?

Ipamorelin is a synthetic pentapeptide that prompts the pituitary gland to release growth hormone by acting on the growth hormone secretagogue receptor.

Raun et al. (1998) introduced ipamorelin as a GH secretagogue and reported that it drove GH release both in vitro and in vivo. In practical terms, it signals the body's own pituitary to secrete GH in pulses, rather than adding GH from outside. This is why the compound sits in the "secretagogue" family alongside agents like CJC-1295 and MK-677, each of which acts on the GH axis through a different route.

Why is ipamorelin called a "selective" GH secretagogue?

Because in animal studies it released growth hormone without the rise in cortisol, ACTH, or prolactin that some earlier secretagogues produced (Raun et al., 1998).

That selectivity was the headline finding. Raun et al. (1998) reported that ipamorelin could release GH while leaving stress-axis hormones such as ACTH and cortisol largely unchanged, a contrast with GHRP-6. In research terms, "selective" here means the effect on GH was not accompanied by the broader hormonal spillover seen with less specific compounds. It does not mean the compound is proven safe or effective in people; that is a separate question the current literature does not answer.

What dosing context did published research actually report?

Published ipamorelin dosing context is preclinical and descriptive, summarized below with its source.

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

The takeaway from the table: the reliable, citable data is about mechanism and relative potency in animals, not a human milligram-per-day figure.

How does ipamorelin compare to CJC-1295 and MK-677?

Each is a GH-axis compound with a different published profile, so they should not be treated as interchangeable.

Ipamorelin's distinguishing feature in the literature is its selectivity for GH release (Raun et al., 1998). CJC-1295 is documented for producing sustained increases in GH and IGF-1 in human subjects (Teichman et al., 2006). MK-677 is an orally active secretagogue, but Nass et al. (2008) reported that it raised fasting glucose and lowered insulin sensitivity in older adults, a reminder that "raises GH" is not the same as "harmless." This page stays focused on ipamorelin dosage as a standalone question; the paired-compound discussion lives on its own page.

Is there human trial data on ipamorelin dosage?

Human dosing evidence is limited, and no large published human dose-ranging trial defines a standard dose here.

The compound's most-cited scientific reference remains preclinical (Raun et al., 1998). Ipamorelin has not completed the trials that would establish a validated human dose or an approved medical use, and published human data stays thin. When a source states a precise human dose as if it were settled science, that claim usually outruns the evidence. Where human data is absent, the accurate framing is that the figure is unverified.

What should guide an ipamorelin dosing decision?

A qualified clinician should, because published research does not provide a validated human dose and individual factors matter.

No page, including this one, can responsibly tell a reader what to take. The published record supports a description of how ipamorelin works and its relative potency in animals (Raun et al., 1998); it does not support a public dosing instruction. Anyone weighing use should route the question to a licensed medical professional who can account for personal health context, lab work, and current regulations. Products described as research compounds are not a substitute for medical care.